The FDA says the cybersecurity vulnerabilities identified may put patients at risk when the device is connected to the ...
Among the wave of guidance documents issued by the U.S. Food and Drug Administration (“FDA” or the “Agency”) in the first week of 2025 were ...
The website changes raise concerns about “the interference of politics with the study and the practice” of science and ...
Dr. Sara Brenner, who has been FDA CDRH's in vitro diagnostics chief medical officer, is serving as acting commissioner of the agency.
The FDA is urging Congress to implement mandatory medical device shortage reporting to address growing vulnerabilities in the ...
“The FDA has made a commitment to advancing health equity as part of the CDRH 2022-2025 Strategic Priorities, including ...
Since the announcement that president-elect Donald Trump would nominate Robert F. Kennedy Jr. (RFK Jr.) as the secretary of the U.S. Department ...
The FDA’s Center for Devices and Radiological Health issued a statement on medical device supply chain vulnerabilities, the public health impact they have on patient care, the FDA’s actions to prevent ...
The FDA is particularly concerned that supply chain issues are having an adverse impact on neonatal and paediatric patients.
De Novo is an approach for the FDA to classify novel medical devices based on risk for devices whose safety and effectiveness can be ensured through general controls or specific controls (i.e., low ...
While medical device shortages are nothing new, the FDA said it is becoming more concerned that supply chain disruptions are ...